Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

ABSTRACT:

Objective

To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment.

Design

Multicenter, randomized clinical trial.

Participants

Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical trial.

Interventions

At enrollment, patients were assigned to 4 treatment groups defined by drug (ranibizumab or bevacizumab) and dosing regimen (monthly or as needed). At 1 year, patients initially assigned to monthly treatment were reassigned randomly to monthly or as-needed treatment, without changing the drug assignment.

Main outcome

SUBMITTER: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group 

PROVIDER: S-EPMC3389193 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature